Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gapped up prior to trading on Thursday . The stock had previously closed at $120.85, but opened at $121.12. Alexion Pharmaceuticals shares last traded at $122.59, with a volume of 1,701,398 shares trading hands.

Several equities research analysts recently weighed in on the stock. Barclays PLC upped their price objective on shares of Alexion Pharmaceuticals from $175.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Monday, May 9th. Leerink Swann reaffirmed an “outperform” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, April 10th. Vetr cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $161.67 price objective for the company. in a research report on Monday, April 4th. Citigroup Inc. raised shares of Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $154.00 price objective for the company in a research report on Monday, June 27th. Finally, BMO Capital Markets assumed coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, April 6th. They set a “market perform” rating and a $165.00 price objective for the company. Eight research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average price target of $193.55.

The stock has a 50-day moving average price of $133.24 and a 200-day moving average price of $146.20. The firm has a market cap of $27.63 billion and a PE ratio of 186.60.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Zacks’ consensus estimate of $1.13 by $0.02. During the same period in the prior year, the company posted $1.28 earnings per share. The business earned $701 million during the quarter, compared to the consensus estimate of $710.98 million. The business’s revenue for the quarter was up 16.8% compared to the same quarter last year. On average, equities analysts anticipate that Alexion Pharmaceuticals Inc. will post $5.06 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, EVP John B. Moriarty sold 918 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $135.72, for a total transaction of $124,590.96. Following the completion of the sale, the executive vice president now owns 51,360 shares of the company’s stock, valued at approximately $6,970,579.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Martin Mackay sold 4,097 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $139.20, for a total value of $570,302.40. Following the sale, the executive vice president now directly owns 42,706 shares of the company’s stock, valued at approximately $5,944,675.20. The disclosure for this sale can be found here.

Several institutional investors recently added to or reduced their stakes in the stock. KBC Group raised its position in Alexion Pharmaceuticals by 46.7% in the third quarter. KBC Group now owns 22,138 shares of the biopharmaceutical company’s stock worth $3,462,000 after buying an additional 7,045 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its position in Alexion Pharmaceuticals by 1.6% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 82,367 shares of the biopharmaceutical company’s stock worth $15,712,000 after buying an additional 1,285 shares during the last quarter. Columbus Circle Investors raised its position in Alexion Pharmaceuticals by 45.5% in the fourth quarter. Columbus Circle Investors now owns 806,802 shares of the biopharmaceutical company’s stock worth $153,897,000 after buying an additional 252,128 shares during the last quarter. ProShare Advisors LLC raised its position in Alexion Pharmaceuticals by 6.0% in the fourth quarter. ProShare Advisors LLC now owns 240,773 shares of the biopharmaceutical company’s stock worth $45,927,000 after buying an additional 13,602 shares during the last quarter. Finally, Comerica Bank raised its position in Alexion Pharmaceuticals by 2.9% in the fourth quarter. Comerica Bank now owns 69,247 shares of the biopharmaceutical company’s stock worth $11,643,000 after buying an additional 1,972 shares during the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.